Healthcare, Pharma & Life Sciences

IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

Image
IDEAYA Sets Phase 3 Design for IDE849 After FDA Type C Meeting

SOUTH SAN FRANCISCO, Calif. -- September 01, 2026 -- IDEAYA Biosciences said its FDA Type C meeting on IDE849, a DLL3-targeting antibody drug conjugate, produced agreement on a Phase 3 registrational trial design for extensive stage small cell lung cancer (ES-SCLC). The Nasdaq-listed company (IDYA) plans to enroll roughly 400 patients who have already received tarlatamab, randomizing them 1:1 between IDE849 monotherapy and an investigator's choice control arm of topotecan and amrubicin. IDEAYA is targeting trial initiation by year-end 2026.

So-Young Revenue Hits RMB505.2M as Aesthetic Treatment Sales Jump 130%

BEIJING -- September 01, 2026 -- So-Young International Inc. (Nasdaq: SY) reported total revenue of RMB505.2 million ($74.5 million) for the second quarter ended June 30, 2026, up 33.4% from RMB378.7 million a year earlier. The Beijing-based aesthetic treatment platform said revenue from its branded aesthetic centers jumped 129.5% to RMB331.4 million, exceeding the high end of its own guidance. Net loss attributable to the company narrowed to RMB22.7 million from RMB36.0 million in the second quarter of 2025.

SIBIONICS Presents AI-Linked GS3 Glucose Sensor at Melbourne Diabetes Congress

Image
SIBIONICS Presents AI-Linked GS3 Glucose Sensor at Melbourne Diabetes Congress

Melbourne, Australia -- September 01, 2026 -- SIBIONICS presented its GS3 continuous glucose monitor at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from August 18 to 21, 2026. The company used Booth #1, a scientific symposium and on-site interviews with credentialled diabetes educators to demonstrate the sensor's AI-linked meal-logging and glucose-trend features. GS3 is a factory-calibrated, 14-day continuous glucose monitor with a 2.9 mm on-body profile.

Philips Wins FDA Clearance for Reusable SpO₂ Sensor Built to Hold Accuracy Across Skin Tones

Image
Philips Wins FDA Clearance for Reusable SpO₂ Sensor Built to Hold Accuracy Across Skin Tones

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has received FDA 510(k) clearance for its next-generation reusable SpO₂ clip sensor, a pulse oximetry device built around internal optical refinements that improve signal quality. In desaturation testing, the sensor posted an accuracy result nearly twice as tight as the level recommended by ISO and recognized by the FDA. It also held accuracy within half a percentage point between light and dark skin pigmentation groups tested. The clearance extends Philips' broader pulse oximetry portfolio and follows a validation program built specifically around performance across diverse patient populations.

Philips Adds Alturion to Ultrasound Line, Targets High-Volume Clinical Workflows

Image
Philips Adds Alturion to Ultrasound Line, Targets High-Volume Clinical Workflows

SHERIDAN, WYOMING -- July 22, 2026 -- Royal Philips has launched Alturion, a new ultrasound system built for departments that run high patient volumes across varied exam types. The system pairs AI-powered workflow tools with imaging hardware designed to hold up across shift changes and multiple users. Alturion has received FDA 510(k) clearance and CE mark certification, making it available now in the U.S. and Europe. Philips positions the launch as an expansion of its ultrasound portfolio rather than a standalone product, built to share transducers and interface design with existing systems already in clinical use.

Roche's Divarasib Beats Approved KRAS G12C Drugs in Head-to-Head Lung Cancer Trial

Image
Roche's Divarasib Beats Approved KRAS G12C Drugs in Head-to-Head Lung Cancer Trial

SHERIDAN, WYOMING -- July 08, 2026 -- Roche announced positive results from the phase III Krascendo 1 study, showing that its investigational KRAS G12C inhibitor divarasib outperformed the approved first-generation inhibitors sotorasib and adagrasib in patients with previously treated KRAS G12C non-small cell lung cancer. The study met both its primary and key secondary endpoints, with divarasib delivering statistically significant improvements in progression-free survival and overall survival. Roche plans to submit the data to health authorities and present full results at an upcoming medical meeting. The company positions the results as evidence that divarasib could become a new treatment standard for this genetically defined subgroup of lung cancer patients.

Dentsply Sirona and HeyGears Validate Lucitone Digital Print Resins for One-Piece Denture Production on UltraCraft MMF Printer

Image
Dentsply Sirona and HeyGears Validate Lucitone Digital Print Resins for One-Piece Denture Production on UltraCraft MMF Printer

SHERIDAN, WYOMING -- June 25, 2026 -- Dentsply Sirona and HeyGears have announced the successful validation of Lucitone Digital Print Denture resins for one-piece denture production on HeyGears' new UltraCraft Multi-Material Fusion DLP 3D printer. The validation extends an existing collaboration between the two companies and establishes a production pathway that eliminates the bonding step previously required to attach Lucitone Digital IPN 3D denture teeth to the denture base. Dental laboratories using the combined workflow can now produce complete monolithic dentures in a single print run while maintaining the mechanical strength, esthetics, and durability associated with the Lucitone material platform. The announcement covers full-arch and partial denture applications.

Dentsply Sirona Names John Fortson CFO to Drive Return-to-Growth Action Plan

Image
Dentsply Sirona Names John Fortson CFO to Drive Return-to-Growth Action Plan

SHERIDAN, WYOMING -- June 15, 2026 -- Dentsply Sirona has appointed John Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026. Fortson joins from Kymera International, where he served as President and CFO, and brings more than 25 years of finance, operations, and strategy experience across global manufacturing and industrial businesses. The appointment is framed by the company as a key step in advancing its Return-to-Growth Action Plan.

VOCO Signs On as Gold Sponsor of FDI World Dental Federation Master CE Programme in Adhesive and Aesthetic Dentistry

Image
VOCO Signs On as Gold Sponsor of FDI World Dental Federation Master CE Programme in Adhesive and Aesthetic Dentistry

SHERIDAN, WYOMING -- June 15, 2026 -- VOCO has become a Gold Sponsor of the FDI World Dental Federation, with the partnership centred on the FDI's Master Continuing Education Programme in adhesive and aesthetic dentistry. The five-module programme delivers specialised clinical training to dental professionals globally, combining theoretical content with practical application under guidance from established speakers in the field. VOCO's sponsorship includes both financial support and provision of composite materials for hands-on use during seminars.

VOCO Launches Fluorescence-on-Demand Portfolio Across Temporary Luting, Core Build-Up, and Aligner Workflows

Image
VOCO Launches Fluorescence-on-Demand Portfolio Across Temporary Luting, Core Build-Up, and Aligner Workflows

SHERIDAN, WYOMING -- June 15, 2026 -- VOCO has introduced a range of fluorescent dental materials spanning temporary luting, temporary filling, core build-up, and aligner attachment workflows. The four products — Bifix Temp fluorescent, Clip F fluorescent, Rebilda DC fluorescent, and AlignerFlow LC — each carry UV-A-activated fluorescence that makes excess material and residues visible without altering aesthetics under natural light. The approach addresses a practical clinical problem: material residues that are difficult to detect with the naked eye but consequential for the quality of subsequent restorations and treatments.